Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Host immune potentiation of drug responses to a murine mammary adenocarcinoma.

× No keyword cloud information.

9 in total

1. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.

Authors: E Proietti; G Greco; B Garrone; S Baccarini; C Mauri; M Venditti; D Carlei; F Belardelli
Journal: J Clin Invest Date: 1998-01-15 Impact factor: 14.808

2. Thymosin alpha 1 restores NK-cell activity and prevents tumor progression in mice immunosuppressed by cytostatics or X-rays.

Authors: Y Umeda; A Sakamoto; J Nakamura; H Ishitsuka; Y Yagi
Journal: Cancer Immunol Immunother Date: 1983 Impact factor: 6.968

3. Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth.

Authors: S Ben-Efraim; R C Bocian; M B Mokyr; S Dray
Journal: Cancer Immunol Immunother Date: 1983 Impact factor: 6.968

4. Cure of mice bearing a late-stage, highly metastatic, drug-resistant tumor by adoptive chemoimmunotherapy.

Authors: M Laude; K L Russo; M B Mokyr; S Dray
Journal: Cancer Immunol Immunother Date: 1993 Impact factor: 6.968

5. Phorbol ester-induced enhancement in lytic activity of CD8+ splenic T cells from low-dose melphalan-treated MOPC-315-tumor bearers.

Authors: L M Weiskirch; B A Baumgartel; E Barker; M B Mokyr
Journal: Cancer Immunol Immunother Date: 1991 Impact factor: 6.968

6. Specificity of the generation and expression of enhanced anti-plasmacytoma immunity by spleen cells from melphalan-treated MOPC-315 tumor bearers.

Authors: M B Mokyr; E Barker
Journal: Cancer Immunol Immunother Date: 1986 Impact factor: 6.968

Host immune potentiation of drug responses to a murine mammary adenocarcinoma.

1. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.

2. Thymosin alpha 1 restores NK-cell activity and prevents tumor progression in mice immunosuppressed by cytostatics or X-rays.

3. Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth.

4. Cure of mice bearing a late-stage, highly metastatic, drug-resistant tumor by adoptive chemoimmunotherapy.

5. Phorbol ester-induced enhancement in lytic activity of CD8+ splenic T cells from low-dose melphalan-treated MOPC-315-tumor bearers.

6. Specificity of the generation and expression of enhanced anti-plasmacytoma immunity by spleen cells from melphalan-treated MOPC-315 tumor bearers.

7. The influence of cytoreductive surgery on the response to chemotherapy of a rat renal cancer.

8. The use of cytotoxic T cells in the regulation of tumour growth in syngeneic mice.

9. Further observations on the effect of cyclophosphamide on intratumor and peripheral leukocyte levels.